MOESM2 of Rationale and design of a multicenter placebo-controlled double-blind randomized trial to evaluate the effect of empagliflozin on endothelial function: the EMBLEM trial

Tanaka, Atsushi; Shimabukuro, Michio; Okada, Yosuke; Taguchi, Isao; Yamaoka-Tojo, Minako; Tomiyama, Hirofumi; Teragawa, Hiroki; Sugiyama, Seigo; Yoshida, Hisako; Sato, Yasunori; Kawaguchi, Atsushi; Ikehara, Yumi; Machii, Noritaka; Maruhashi, Tatsuya; Shima, Kosuke; Takamura, Toshinari; Matsuzawa, Yasushi; Kimura, Kazuo; Sakuma, Masashi; Oyama, Jun-ichi; Inoue, Teruo; Higashi, Yukihito; Ueda, Shinichiro; Node, Koichi

doi:10.6084/m9.figshare.c.3741143_D2.v1

12933_2017_532_MOESM2_ESM.docx (20.48 kB)

MOESM2 of Rationale and design of a multicenter placebo-controlled double-blind randomized trial to evaluate the effect of empagliflozin on endothelial function: the EMBLEM trial

journal contribution

posted on 2017-04-12, 05:00 authored by Atsushi Tanaka, Michio Shimabukuro, Yosuke Okada, Isao Taguchi, Minako Yamaoka-Tojo, Hirofumi Tomiyama, Hiroki Teragawa, Seigo Sugiyama, Hisako Yoshida, Yasunori Sato, Atsushi Kawaguchi, Yumi Ikehara, Noritaka Machii, Tatsuya Maruhashi, Kosuke Shima, Toshinari Takamura, Yasushi Matsuzawa, Kazuo Kimura, Masashi Sakuma, Jun-ichi Oyama, Teruo Inoue, Yukihito Higashi, Shinichiro Ueda, Koichi Node

Additional file 2. AESI definitions.

Funding

Nippon Boehringer Ingelheim

History

Usage metrics

Keywords

Empagliflozin Endothelial function Reactive hyperemia peripheral arterial tonometry (RH-PAT)Sodium glucose cotransporter 2 (SGLT2) inhibitor Type 2 diabetes mellitus (T2DM)

Licence

CC BY + CC0

Exports

RefWorks

BibTeX

Ref. manager

Endnote

DataCite

NLM

DC

MOESM2 of Rationale and design of a multicenter placebo-controlled double-blind randomized trial to evaluate the effect of empagliflozin on endothelial function: the EMBLEM trial

Funding

Nippon Boehringer Ingelheim

History

Usage metrics

Categories

Keywords

Licence

Exports